Pay in 4 interest-free payments of $6.95 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
If you experienced diarrhea or fluid loss during prep, electrolyte-balanced beverages can help restore balance before your next dose
GLP-1 medication coverage depends on your specific plan
We think Amgen's going to be an important participant in this global health crisis. Amgen joins an increasingly competitive field: Eli Lilly recently saw its chronic weight product, injectable ZepBound (tirzepatide), approved by the FDA, while Novo Nordisk already has two weight-loss peptides on the market, Saxenda (liraglutide) and Wegovy (semaglutide)
The dual-agonist approach appears to produce greater glycemic control and weight reduction compared to selective GLP-1 receptor agonists in clinical trials
Obesity with hepatic steatosis : Patients with BMI 30 kg/m (or 27 kg/m with weight-related comorbidities) and documented fatty liver may benefit from GLP-1 agonists approved for chronic weight management
US$ 22.58
US$ 25.73
US$ 24.88
US$ 22.08
US$ 22.49
US$ 22.97
